Neurocrine Biosciences | NBIX - Les Intérêts Débiteurs Sur La Dette





Les Intérêts Débiteurs Sur La Dette Changement Date
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
ALKERMES USD 12.28M 7.63M 2025-12
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amgen USD 657M 4M 2026-03
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Cytokinetics USD 30.33M 4.01M 2025-12
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 255M 1000K 2025-12
Halozyme Therapeutics USD 4.91M 615K 2025-12
Incyte USD 569K 13K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 711M 59M 2025-12
Prothena USD 2.62M 350M 2025-12
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Repligen USD 5.5M 81K 2025-12
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Teva Pharmaceutical Industries USD 216M 4M 2026-03
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xoma USD 3.4M 150K 2024-06